奥沙利铂联合氟尿嘧啶治疗晚期胃癌临床研究

Clinical Study on Patients with Advanced Gastric Cancer Treated with OLF Regimen

目的评价奥沙利铂(OXA)联合甲酰四氢叶酸钙(LV)和氟尿嘧啶(5-Fu)方案治疗晚期胃癌的近期疗效和毒性反应。方法26例晚期胃癌,给予OLF方案,即OXA130mg/m2静脉滴注4hd1,LV200mg/m2静脉滴注2hd1-5,5-Fu300mg/m2静脉滴注6hd1-5,每3周为一周期。按WHO标准评价近期疗效和毒性反应;同时观察TTP和MST。结果可评价疗效者26例,治疗后获得CR1例(3.8%),PR8例(30.8%),SD8例(30.8%),PD9例(34.6%),总有效率34.6%。至2007年12月,中位疾病进展时间(TTP)为5.2个月,中位生存期(MST)为8.6个月。主要毒性反应为恶心、呕吐、骨髓抑制及一过性感觉异常,全组无治疗相关性死亡。结论OXA联合LV/5-Fu组成的OLF方案治疗晚期胃癌患者有效,临床缓解率较高,不良反应轻,可以耐受。

Objective To evaluate the efficacy and toxicity of oxaliplatin（OXA） in combination with 5-fluorouraeil（5-Fu） and leucovorin （LV） in the treatment of advanced gastric cancer. Methods 26 patients with advanced gastric cancer enrolled. All patients received modified OLF regimen,namely OXA 130 mg/m^2 iv 4 h d1, LV 200 mg/m^2 iv 2 h d1-5 ,5-Fu 300 mg/m^2 iv 6 h d1-5 ,repeated every 3 weeks. The efficacy and toxicity were evaluated according to WHO standard. Results All patients might be evaluated for clinical response,CR was observed in 1 patient（3.8% ） and PR in 8（30.8% ） ,SD in 8（30.8% ） ,PD in 9（34. 6% ）. The total response rate （ CR ＋ PR） was 34.6%. Median time to progression （TTP） was 5.2 months, median overall survival time（MST） was 8.6 months. The most common toxicities were nausea, vomiting, suppression of marrow and mild neuro-sorv abnormity. There was no treatment related death. Conclusion OXA in combination with 5-Fu and LV is an effective and well tolerated regimen in the treatment of advanced gastric cancer with mild toxicity.